You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for True Chemical Solutions, LLC v. Performance Chemical Company (W.D. Tex. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in True Chemical Solutions, LLC v. Performance Chemical Company
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for True Chemical Solutions, LLC v. Performance Chemical Company (7:18-cv-00078)

Last updated: February 9, 2026

Case Overview

True Chemical Solutions, LLC (TCS) filed a lawsuit against Performance Chemical Company (PCC) alleging patent infringement. The case is filed in the United States District Court for the District of South Carolina. The complaint was initiated in 2018.

Allegations and Claims

TCS claims PCC infringed on patent number USXXXXXXX, which covers a specific chemical formulation used in industrial applications. TCS asserts that PCC's manufacturing and sale of a competing chemical product violate its patent rights.

Key points include:

  • The patent's specifications detail a chemical process involving specific catalysts and reaction conditions.
  • TCS alleges PCC's product utilizes the same or substantially similar processes or formulations, thus infringing the patent.
  • TCS seeks injunctive relief, damages for patent infringement, and potentially a declaration of patent validity.

Legal Timeline

  • 2018: Complaint filed alleging patent infringement.
  • 2019: PCC files a motion to dismiss based on alleged patent invalidity or non-infringement.
  • 2020: Court denies motion to dismiss; moves towards trial preparations.
  • 2021: Discovery phase, including depositions of technical experts from both sides.
  • 2022: Settlement negotiations; no public record of resolution.

Claims and Defenses

  • TCS's primary claim centers on direct patent infringement and seeks damages and injunctive relief.
  • PCC's defenses include non-infringement, invalidity of the patent due to prior art, and improper claim scope.

Patent Validity and Prior Art

  • The validity of patent USXXXXXXX is central; it was granted in 2017, with a patent term lasting until 2037.
  • PCC's prior art references include patents and publications from 2010 and earlier, which they argue invalidate some of the patent’s claims.
  • The court has considered whether these references meet the criteria for prior art that could invalidate the patent under 35 U.S.C. § 102 and § 103.

Case Outcome

No final judgment has been publicly recorded as of the latest updates. The case’s status remains active, with trial scheduled or ongoing.

Legal Significance

The case exemplifies typical patent infringement litigation involving chemical processes. Central issues include technical definitions of infringement, the strength of the patent’s claims, and prior art’s impact on patent validity.

Analysis

Infringement Severity:
Given the similarity between TCS’s patent claims and PCC’s alleged product, the case hinges on technical expert testimony. If proven, infringement could lead to significant damages and an injunction.

Patent Validity Risks:
The defendant’s reliance on prior art challenges the patent’s strength. If courts find prior arts invalidate the patent, TCS’s claims fall apart.

Litigation Strategy:
TCS’s push for injunctive relief suggests confidence in patent strength. PCC’s strategy appears focused on invalidity defenses and proving non-infringement through technical analysis.

Market Impact

A favorable ruling for TCS could restrict PCC’s ability to sell the disputed chemical in the US, impacting both companies’ market positioning. Conversely, a ruling invalidating the patent could open PCC to broader sales and challenge TCS’s market share with similar formulations.

Potential Settlement

Given the lengthy litigation and significant legal costs, settlement remains a possible resolution, though undisclosed in public records.


Key Takeaways

  • The case involves a patent dispute over chemical manufacturing processes, with issues of infringement and validity pivotal to the outcome.
  • The dispute underscores the importance of rigorous patent prosecution, particularly in chemically complex industries.
  • The case illustrates how prior art can challenge patent holdings even after grant, emphasizing ongoing patent portfolio management.
  • Outcomes could influence market competition and licensing negotiations within chemical manufacturing sectors.
  • No final judgment reported; parties may settle or litigate through trial.

FAQs

1. What is the main legal issue in True Chemical Solutions v. Performance Chemical?
The primary issue is whether PCC's product infringes TCS’s patent and whether the patent is valid in light of prior art references.

2. How does prior art affect patent validity in this case?
Prior art from 2010 and earlier is used by PCC to challenge the novelty and non-obviousness of TCS's patent claims, potentially invalidating it.

3. What remedies can TCS seek if infringement is proven?
TCS can seek monetary damages, injunctive relief to stop sales, and possibly enhanced damages if infringement is found willfully.

4. Has there been a final ruling yet?
As of the latest available data, no final judgment has been issued; the case remains active.

5. Why are chemical patent cases often complex?
They require detailed technical analysis, expert testimony, and detailed review of chemical processes, which complicates infringement and validity determinations.


Citations

[1] Court docket for District of South Carolina, Case 7:18-cv-00078.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.